Nanoparticle-Enhanced Drug Delivery Systems for Cardiovascular Applications
Summary
Cardiovascular diseases remain the leading global cause of morbidity and mortality, driving the need for therapies that can precisely deliver pharmacological agents to diseased myocardium while minimising systemic side effects. Nanoparticle-based drug delivery systems harness a diverse array of materials—liposomes, polymeric constructs, inorganic crystals and hybrid composites—to encapsulate small molecules, peptides or genetic cargos. Passive targeting exploits the enhanced permeability of injured or inflamed cardiac tissue, whereas active strategies employ surface functionalisation with antibodies, peptides or aptamers to bind specific cellular markers. Stimuli-responsive designs (pH, redox or enzyme-sensitive) enable on-site drug release, and advanced routes such as inhalation or cell-mediated “hitchhiking” on circulating leucocytes further improve localisation. Key challenges include evading immune clearance, ensuring biocompatibility, scaling up reproducible formulations and translating promising preclinical outcomes into clinical efficacy. Collectively, nanoparticle platforms offer a path towards precision cardiology by enhancing therapeutic indices, reducing dosing frequency and opening avenues for regenerative and gene therapies in myocardial infarction, heart failure and vascular disease.
Research from Nature Portfolio
Recent studies have introduced an inhalable cardiac-targeting peptide-modified calcium phosphate nanoparticle that markedly enhances delivery of a phosphodiesterase inhibitor to failing myocardium via pulmonary administration, attenuating remodelling and improving function through modulation of cAMP/AMPK and cGMP/PKG signalling pathways without significant off-target toxicity. Another foundational work has demonstrated that systemically administered PEG-modified polystyrene nanoparticles between 20 and 200 nm preferentially accumulate in ischaemic myocardium shortly after reperfusion, establishing size-dependent passive targeting principles for optimising biodistribution post-infarction.
Nanoparticle-Enhanced Drug Delivery Systems for Cardiovascular Applications publication trend
The graph below shows the total number of articles in nanoparticle-enhanced drug delivery systems for cardiovascular applications across all publications each year (not limited to Nature Index journals).
Technical terms
Nanoparticle: A submicrometre-scale carrier capable of encapsulating therapeutic agents for controlled delivery.
Passive targeting: Accumulation of nanoparticles in diseased tissue driven by their size, shape and inherent tissue permeability.
Active targeting: Surface functionalisation of nanoparticles with ligands or peptides to bind specific cellular receptors.
Peptide-guided targeting: Use of receptor-affinity peptides to steer nanoparticles towards myocardial cells or inflamed vasculature.
Macrophage hitchhiking: Strategy whereby nanoparticles associate with monocytes/macrophages to exploit their homing to sites of injury or inflammation.
pH-responsive release: Design of nanoparticle matrices that destabilise and release payloads under acidic conditions found in pathological microenvironments.
References
- Macrophage Hitchhiking Nanoparticles for the Treatment of Myocardial Infarction: An In Vitro and In Vivo Study. Advanced Functional Materials (2023).
- Inhalable cardiac targeting peptide modified nanomedicine prevents pressure overload heart failure in male mice. Nature Communications (2024).
- Distribution of Systemically Administered Nanoparticles Reveals a Size-Dependent Effect Immediately following Cardiac Ischaemia-Reperfusion Injury. Scientific Reports (2016).
- Application of the Nano-Drug Delivery System in Treatment of Cardiovascular Diseases. Frontiers in Bioengineering and Biotechnology (2020).
- Nanostructured Polymeric, Liposomal and Other Materials to Control the Drug Delivery for Cardiovascular Diseases. Pharmaceutics (2020).
- Nanocarrier-Based Targeted Therapies for Myocardial Infarction. Pharmaceutics (2022).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.